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1  | INTRODUC TION
Worldwide	populations	are	aging	with	economic	development	as	a	
result	 of	 public	 health	 initiatives	 and	 advances	 in	 therapeutic	 dis-
coveries.	 Since	 1850,	 life	 expectancy	 has	 advanced	 by	 1	year	 for	
every	four.1	Accompanying	this	change	is	the	rapid	development	of	
anti‐aging	science.	There	are	three	schools	of	thought	in	the	field	of	
aging	 science.	One	perspective	 is	 the	 life	 course	 approach,	which	
considers	that	aging	is	a	good	and	natural	process	to	be	embraced	
as	a	necessary	and	positive	aspect	of	 life,	where	 the	aim	 is	 to	 im-
prove	 the	 quality	 of	 existing	 lifespan	 and	 “compress”	 morbidity.	
Another	view	is	that	aging	is	undesirable,	and	that	rejuvenation	and	
indeed	immortality	are	possible	since	the	biological	basis	of	aging	is	
understood,	 and	 therefore,	 strategies	 are	possible	 for	 engineering	
negligible	senescence.	Finally,	a	hybrid	approach	is	that	life	span	can	
be	extended	by	anti‐aging	medicines	but	with	uncertain	effects	on	
health.	While	these	advances	offer	much	promise,	 the	ethical	per-
spectives	 are	 seldom	 discussed	 in	 cross‐disciplinary	 settings.	 This	
article	discusses	some	of	the	key	ethical	 issues	arising	from	recent	
advances	in	biogerontology.
2  | ADVANCES IN GEROSCIENCE
The	biological	basis	of	aging	is	increasingly	understood,	and	myriad	
ways	 of	 altering	 aging	 are	 now	 known.	One	 cause	 of	 aging	 is	 the	
accumulation	 of	 molecular	 damage,	 such	 as	 DNA	 mutations	 and	
misfolded	proteins.	Damage	can	further	lead	to	“meta‐effects,”	such	
as	the	emergence	of	senescent	cells	or	dysfunctional	mitochondria,	
which	contribute	 to	a	 feedback	 loop	of	damage	and	dysfunction.2 
These	deleterious	causes	of	aging	are	offset	by	endogenous	repair	
and	 rejuvenation	 pathways,	many	 of	which	 are	 linked	 to	 nutrition	
and	metabolism.	Dozens	of	genetic,	pharmacological,	and	other	in-
terventions	can	slow	aging	in	the	laboratory,	in	species	ranging	from	
yeast	to	non‐human	primates.	Two	major	classes	of	interventions	are	
currently	entering	human	clinical	trials.	One	class	activates	nutrient	
signaling	pathways	to	turn	on	endogenous	repair	and	rejuvenation	
pathways.	The	other	class	targets	deleterious	meta‐effects	of	aging,	
such	as	senescent	cells	or	stem	cell	dysfunction.	Metformin	is	a	dia-
betes	drug	that	appears	to	activate	aging‐related	nutrient	signaling	
pathways.3	A	large	randomized	controlled	trial	to	test	if	metformin	
can	delay	age‐related	multimorbidity	is	being	planned	in	the	United	
States.	 Inhibitors	of	the	protein‐sensing	TOR	complex	can	activate	
protein	repair	pathways	and	extend	lifespan	in	the	laboratory,4 and 
a	clinical	trial	recently	showed	that	TOR	inhibitors	can	prevent	res-
piratory	infections	in	vulnerable	elderly	patients.5	Drugs	that	restore	
the	metabolic	signaling	molecule	NAD6	and	activate	NAD‐depend-
ent	 sirtuin	enzymes	are	also	under	 investigation.7,8	Eliminating	se-
nescent	cells	extends	healthy	lifespan	in	the	laboratory	by	reducing	
damaging	inflammation,9,10	and	a	number	of	drugs	to	target	senes-
cent	cells	are	entering	clinical	trials.11	Stem	cells	can	be	rejuvenated	
in	 the	 laboratory	 with	 factors	 derived	 from	 young	 blood,12 or by 
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direct	infusion	of	healthy	stem	cells.	Both	approaches	are	now	being	
studied	in	clinical	trials	to	treat	physical	frailty13	and	dementia.14 In 
the	future,	direct	genome	editing	could	be	used	to	treat	aging.15	An	
international	 consortium	 is	 working	 to	 move	 anti‐aging	 therapies	
more	rapidly	into	clinical	trials.16
3  | TECHNOLOGIC AL ADVANCES
If	maintenance	 of	 function	 rather	 than	 life	 extension	 is	 a	 key	 de-
sirable	outcome	during	 the	aging	process,	 then	 technology	has	an	
important	role	in	achieving	this	goal	in	the	presence	of	physical	dis-
abilities	as	well	as	cognitive	function	impairments.
Stroke	 is	 a	 commonly	 encountered	disease	 that	 increases	with	
age	and	is	a	major	contributor	to	disability	burden.	Advances	in	tech-
nology‐assisted	rehabilitation	are	developing	rapidly	 in	augmenting	
neuroplasticity	during	the	recovery	period	through	the	use	of	exo-
skeleton	 robotics.	 Robotics	 are	 also	 being	 used	 for	 surgical	 pro-
cedures	 to	 improve	 accuracy,	 and	 to	 a	 smaller	 extent,	 service	 and	
companion	robots	are	being	developed	and	adopted	in	care	of	older	
people	with	physical	and	cognitive	impairments.	Artificial	intelligence	
is	being	applied	to	diagnosis	and	treatment	using	algorithms.	Another	
rapidly	developing	field	involves	surveillance	of	older	people	in	hos-
pitals	or	residential	care	settings,	as	well	as	at	home,	to	prevent	ad-
verse	outcomes,	such	as	falls,	accidents,	acute	medical	conditions	for	
which	older	people	may	have	reduced	ability	to	call	for	help,	and	also	
for	health	maintenance	 (monitoring	of	drug	compliance,	vital	signs,	
activity	patterns).	Older	adults	are	not	always	involved	in	the	devel-
opment	or	deployment	of	these	systems.	For	both	biogerontological	
research	and	gerotechnological	developments,	other	than	address-
ing	the	scientific	question,	the	needs	of	older	people	should	also	be	a	
driver	and	hence	older	people's	input	is	desirable.
4  | ETHIC AL PERSPEC TIVES
4.1 | Is aging a disease?
It	 is	 commonly	assumed,	 in	 the	debate	on	 the	ethics	of	 anti‐aging	
research,	that	the	question	of	whether	aging	is	a	disease	or	not	car-
ries	 high	 normative	 significance.	 For	 instance,	 some	 people	 hold	
that	if	(and	only	if)	aging	is	a	disease,	then	it	is	an	appropriate	target	
for	medical	 intervention;	otherwise	 it	 is	not.	On	a	more	pragmatic	
note,	it	seems	clear	that	being	able	to	label	aging	as	a	disease	would	
facilitate	access	to	research	funding,	 the	 initiation	of	clinical	 trials,	
and	potential	coverage	of	future	anti‐aging	interventions	by	medical	
insurance.
The	question	of	whether	aging	is	a	disease	or	not	depends	on	
how	we	should	understand	disease	and	health,	which	is	a	conten-
tious	 issue	 in	 the	 philosophy	 of	 medicine.	 One	 approach	 holds	
that	disease	is	a	departure	from	“normal”	human	functioning,	and	
that	if	a	condition	is	universal	and	the	result	of	internal	biological	
processes,	it	cannot	be	abnormal.17	Since	all	humans	age,	this	ap-
proach	implies	that	aging	itself	is	not	abnormal,	and	therefore	not	
a	disease.	On	a	different,	conflicting	approach,	any	condition	that	
demonstrates	sufficient	structural	similarity	with	paradigm	exam-
ples	of	disease	should	itself	be	regarded	as	a	disease,	even	if	it	is	
universally	shared.	Some	authors	have	argued	that	this	description	
applies	to	aging.18
When	 it	 comes	 to	 establishing	 the	medical	 legitimacy	 of	 anti‐
aging	 interventions,	 it	 might	 be	 possible	 to	 sidestep	 that	 difficult	
issue	 by	 considering	 the	 fact	 that	 a	 medical,	 preventive	 rationale	
can	be	offered	for	slowing	down	(or,	if	at	all	possible,	reversing)	the	
aging	process,	regardless	of	its	status	as	a	disease.	Indeed,	a	growing	
number	of	biogerontologists	are	suggesting	that	doing	so	might	help	
delay,	if	not	prevent	completely,	the	advent	of	diseases	like	cancer,	
Alzheimer's,	or	cardiovascular	disease.	That	being	said,	the	existence	
of	such	a	medical	rationale	does	not	automatically	put	an	end	to	the	
ethical	debate	about	the	overall	permissibility	of	this	kind	of	 inter-
vention:	at	least	in	principle,	it	could	be	overridden	by	countervailing	
considerations.	Neither	does	it	show	that	the	question	of	the	status	
of	aging	as	a	disease	can	be	avoided	completely,	if	only	because	of	
the	significant	practical	 implications	of	 the	answer	 that	we	collec-
tively	decide	to	give	to	that	question,	as	mentioned	previously.
Still,	it	would	seem	that	the	preventive	rationale	for	anti‐aging	med-
icine	is	not	always	sufficiently	taken	into	account	in	the	ethical	debate.	
The	onus	is	on	those	who	oppose	intervening	in	the	aging	process	to	
offer	an	explanation	as	to	why	the	putative	undesirability	of	doing	so	
outweighs	the	preventive	rationale	for	intervention.	Without	prejudg-
ing	whether	they	can	succeed,	one	can	at	least	note	that	it	is	important	
for	them	not	to	confuse	the	effects	of	biological and chronological aging. 
Of	course,	the	same	point	applies	to	those	who	support	anti‐aging	re-
search:	They	must	take	care	not	to	overestimate	the	potential	impact	
of	such	research	on	the	diseases	of	the	elderly—on	this,	it	is	primarily	
scientific	experts	who	can	provide	the	needed	reality	check.19
4.2 | Life extension, justice, and equity
Modern	medical	 science	 could	 give	 humans	 an	 extended	 lifespan,	
increased	life	expectancy	at	birth,	and	a	compression	of	morbidity	in	
late	life.	Would	this	be	desirable?	An	extended	life	is	not	(yet)	the	im-
mortality	that	has	been	viewed	by	some	philosophers	(e.g.,	Bernard	
Williams)	as	undesirable	for	being	intolerably	“boring”	and	as	under-
mining	the	conditions	of	continued	identity.20
Reasons	for	and	against	extending	 life	may	be	divided	 into	the	
personal	and	external.	The	latter	 include	the	increased	costs	of	an	
older	population.	But	 it	 is	not	clear	that	this	 is	problematic	 if	mor-
bidity	 is	compressed.	Moreover,	 longer	 lives	 increase	the	temporal	
discounting	of	costs,	as	well	as	the	number	of	productive	years.
It	 is	 also	not	evident	 that	extended	 lives	mean	 that	 the	young	
would	unfairly	subsidize	the	old	if	we	adopt	a	whole‐life	perspective	
and	think	in	terms	of	turn‐taking.
Longer	 lives	might,	 of	 course,	mean	more	 lives	 and	 thus	 raise	
population	ethics	issues.	Yet	the	evidence	here	is	unclear.	Moreover,	
the	extensions	envisaged	by	geroscience	need	not	be	dramatic;	and	
the	problematic	pressure	on	global	resources	is	a	broader	one	than	
that	of	prolonging	human	lives.
     |  101COMMENTARY
It	would	not	be	ethically	problematic	to	control	reproduction	and	
thereby	balance	a	right	to	a	longer	life	against	a	right	to	procreate.
Personal	reasons	to	want	more	life	are	for	more	of	what	life	of-
fers.	Such	reasons	for	longer	life	should	be	clearly	distinguished	from	
impersonal	reasons	for	longer	life.	Whether	everyone	has	such	rea-
sons	is	doubtful.	If	Williams	is	right	that	longer	life	will	be	intolerably	
boring	and	undermine	the	conditions	of	continued	identity,	after	a	
certain	age	(which	might	differ	from	person	to	person)	they	will	not.
Concerns	are	 likely	 to	be	 raised	about	 justice	when	consider-
ing	any	interventions	to	extend	life.	One	source	of	such	concerns	
centers	 on	 the	 ease	with	which	people	 can	 access	 the	 results	 of	
biogerontological	research.	Where	doing	so	is	expensive,	it	is	likely	
that	the	beneficiaries	will	primarily	be	those	who	are	already	better	
off—resulting	in	longer	lives	for	the	rich	alone.	But	even	with	equal	
access,	concerns	about	the	justice	of	biogerontological	research	re-
main.	This	is	because	differences	in	adult	life	expectancy,	tracking	
socioeconomic	status,	already	exist	in	all	societies.	In	general,	the	
rich	live	longer	lives,	on	average,	than	the	poor—something	that	can	
largely	be	explained	by	social	and	environmental	factors.21,22 While 
work	in	biogerontology	does	not	directly	address	those	factors,	it	
has	 the	 potential	 to	 either	 reduce	 or	 exacerbate	 their	 impact.	 In	
doing	so	it	can	either	increase	or	decrease	health	inequality.
However,	 inequality	 is	also	 inherently	human.	Some	people	on	
reaching	an	advanced	age	feel	as	though	they	have	already	lived	life	
to	its	fullest,	and	do	not	feel	the	need	to	extend	it	further.	It	may	or	
may	not	be	 that	what	 life	has	 to	offer	 them	 is	not	something	 that	
they	care	to	extend.	The	structural	conditions	of	their	lived	lives	may	
already	have	been	patterned	by	social	inequality	at	a	very	basic	level.
For	 this	 reason,	 assessing	 the	 ethical	 acceptability	 of	 work	 in	
biogerontology	 requires	 taking	account	of	 its	 impact	on	both	 indi-
viduals	and	society.	Doing	so	is	not	easy.	It	requires	answering	three	
questions.	 First,	what	 are	 the	overall	 benefits,	 and	how	will	 those	
benefits	be	distributed?	Second,	what	 is	the	 likely	effect	on	health	
inequality,	and	would	alternative	ways	of	using	resources	affect	in-
equality	differently?	Third,	how	should	we	balance	increases	in	well-
being	 against	 increases	 in	 inequality	where	 these	 occur?	 The	 first	
two	questions	are	empirical.	The	answers	will	depend	not	only	on	the	
nature	of	the	research.	They	will	also	depend	on	the	social	structures	
and	makeup	of	each	society.	That	 is	because	how	new	treatments	
and	interventions	affect	health	inequality	is	likely	to	vary	with	exist-
ing	levels	of	inequality,	and	systems	of	governance	and	welfare	pro-
vision.	The	final	question	is	normative	and	requires	an	assessment	of	
how	different	values	should	be	balanced	where	they	come	into	con-
flict.23-26	Answering	these	questions	cannot	be	done	in	the	abstract,	
and	for	each	case	will	require	a	multidisciplinary	approach	that	brings	
together	scientists,	economists,	political	scientists,	and	ethicists.27
4.3 | The good and the bad (misapplications)
Research	 and	development	 in	 the	 field	 of	 anti‐aging	medicine	has	
fueled	 a	 multi‐	 billion	 dollar	 industry	 in	 the	 past	 decade,28	 with	
the	 largest	 proportion	 spent	 on	 integration	 of	 large	 omics	 data-
sets	 to	 find	 patterns	 in	 age‐related	 diseases	 and	 the	 therapy	 of	
neurodegenerative	diseases.	While	there	are	robust	guidelines	regu-
lating	clinical	research	in	humans	in	the	form	of	clinical	research	eth-
ics	committees,	the	regulation	of	unjustified	and	misleading	claims	
about	anti‐aging	products	together	with	unethical	clinical	practices	
is	 problematic.	 Aggressive	marketing	 and	misleading	 claims	 in	 the	
pursuit	of	profit	are	not	uncommonly	encountered.	This	industry	is	
fueled	by	a	universal	desire	 (albeit	subconscious)	to	remain	young,	
as	well	as	the	attraction	of	taking	a	product	(medicines,	hormones,	
dietary	supplements)	 instead	of	changing	behavior	 to	 lead	healthy	
lifestyles,	even	though	there	is	ample	evidence	of	the	health	benefits	
of	the	latter.	The	recent	case	of	gene	editing	of	an	implanted	human	
embryo	 in	a	private	 facility	 illustrates	how	regulatory	mechanisms	
have	failed	to	keep	pace	with	activities	in	these	fields,	even	though	
there	have	been	widespread	discussions	on	the	ethical	perspectives	
of	 gene	 editing,	 where	 there	 remains	 uncertainty	 regarding	 long	
term	side‐effects	of	irreversibly	altering	the	human	germ	cell	line.29
4.4 | Issues relating to artificial 
intelligence and robotics
Various	ethical	 issues	need	 to	be	 flagged	up	 relating	 to	 the	above	
developments.	 The	 use	 of	 robotic	 surgical	 techniques	 needs	 to	
be	 regularly	 audited	 to	 evaluate	 performance	 and	 complications.	
Similar	 data	 are	 needed	 for	 service	 and	 companion/social	 robots.	
Widespread	 use	will	 depend	 on	 cost‐benefit	 analyses,	which	may	
guide	 governments	 to	 decide	 on	 financing,	 and	 this	will	 raise	 de-
bates	regarding	prioritization	in	health	care	and	issues	of	justice,	as	
discussed	 above.	 Promising	 use	 of	 artificial	 intelligence	 and	 deep	
learning	with	big	datasets	from	other	industries	is	being	introduced	
to	health	care	with	the	availability	of	healthcare	informatics	and	evi-
dence‐based	medicine.	Although	this	is	predominantly	led	by	com-
mercial	companies,	many	clinicians	and	data	scientists	are	beginning	
to	work	together	to	determine	how	this	may	impact	on	clinical	prac-
tice.	Algorithms	in	diagnosis	and	management	are	determined	by	cli-
nicians	based	on	the	latest	evidence.	The	latter	changes	with	time,	
and	also	there	are	many	clinical	scenarios	for	which	evidence	based	
on	randomized	controlled	trials	 is	not	available,	particularly	among	
frail	elderly	populations,	women,	and	people	of	various	ethnicities	
who	tend	not	to	be	included	or	are	included	in	inadequate	numbers	
to	reach	a	definite	conclusion.	There	are	also	 issues	with	potential	
misuse	of	patient	data	and	the	legal	framework	if	there	are	adverse	
outcomes.	Nevertheless,	machine	learning	would	facilitate	diagnosis	
and	prognosis	as	an	aid	to	doctors	to	manage	increasing	complexity;	
yet	the	“human”	attributes	of	a	doctor‐patient	relationship	that	dis-
tinguishes	a	good	doctor	would	be	difficult	to	replace.30-32
4.5 | Ethics and policies
Ethical	recommendations	as	to	what	is	permissible,	obligatory,	or	im-
permissible	are	clearly	distinct	from	proposals	to	make	a	 law	or	to	
institute	a	policy.	What	is	needed	for	proposals	of	this	latter	kind	is	a	
sense	both	of	what	is	defensible	and	of	what	is	feasible	given	existing	
laws,	institutions,	and	practices,	as	well	as	public	opinion.
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Changes	in	law	and	policy	can	and	should	best	be	made	by	orga-
nizations	that	are	sensitive	to	social	and	political	realities,	well	con-
nected	to	policy‐makers,	and	able	to	engage	in	objective	evaluation	
of	issues.	The	Nuffield	Council	on	Bioethics	is	such	an	organization.	It	
is	an	independent	body	within	the	United	Kingdom	that	examines	and	
reports	on	ethical	issues	in	biology	and	medicine.	It	was	established	
by	the	Trustees	of	the	Nuffield	Foundation	in	1991,	and	since	1994	it	
has	been	funded	jointly	by	the	Foundation,	the	Wellcome	Trust,	and	
the	Medical	Research	Council.	The	Council	has	achieved	an	interna-
tional	reputation	for	advising	policy‐makers	and	stimulating	debate	
in	bioethics.	It	functions	very	much	as	the	United	Kingdom's	national	
bioethics	committee.	Its	terms	of	reference	are:	to	identify	and	de-
fine	 ethical	 questions	 raised	 by	 recent	 developments	 in	 biological	
and	medical	research	that	concern,	or	are	likely	to	concern,	the	public	
interest;	to	make	arrangements	for	the	independent	examination	of	
such	questions	with	appropriate	involvement	of	relevant	stakehold-
ers;	to	inform	and	engage	in	policy	and	media	debates	about	those	
ethical	questions	and	provide	informed	comment	on	emerging	issues	
related	to	or	derived	from	the	Council's	published	or	ongoing	work;	
and	to	make	policy	recommendations	to	government	or	other	rele-
vant	bodies	and	to	disseminate	its	work	through	published	reports,	
briefings,	and	other	appropriate	outputs.	Many	changes	 in	 law	and	
policy	within	the	United	Kingdom—such	as	the	legislation	to	permit	
mitochondrial	replacement	treatment—can	be	attributed	to	the	work	
of	the	Council.	Recommendations	within	Council	reports	may	also	be	
adopted	by	professional	bodies.	Its	horizon‐scanning	activities	allow	
it	to	identify	those	topics,	arising	from	new	developments,	that	might	
fall	within	this	remit.	It	is	for	the	Council	then	to	decide	on	whether	
to	engage	in	work	on	any	particular	topic.	This	work	could	take	the	
form	of	 a	major	 report	 or	 only	 the	preparation	of	 a	 short	 briefing	
note	that	can	provide	policy‐makers	and	relevant	stakeholders	with	
a	clear	sense	of	the	scope	of	the	topic	and	of	the	relevant	social,	eth-
ical,	and	legal	issues.	The	Council	has	already	produced	an	eight‐page	
briefing	note	on	“The	search	for	a	treatment	for	aging.”33	Should	cir-
cumstances	or	developments	make	it	important	to	produce	a	longer	
report,	the	Council	would	be	able	to	do	so.
5  | CONCLUSION
Scientists,	 gerontologists/geriatricians,	 economists,	 engineers,	
bioethicists,	and	politicians	should	take	a	truly	cross‐disciplinary	com-
prehensive	approach,	with	formation	of	regulatory	bodies	accounta-
ble	to	governments,	and	development	of	mechanisms	for	monitoring.	
Current	clinical	research	ethics	committees	may	need	to	be	expanded	
to	 link	with	government	 regulatory	bodies.	The	exact	 requirements	
will	likely	depend	on	variations	in	development	in	this	area	in	different	
countries;	there	would	be	an	advantage	to	the	formation	of	a	trans-
national	organization	following	the	principles	of	the	Nuffield	Council.
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